

# *Perioperative Anesthetic Management In Heart Transplanted Recipients Undergoing Noncardiac Surgery*

Essay

Submitted for partial fulfilment of master degree in anesthesiology

By

*Sherin Dawoud Youssef*

M.B.B, CH.

SUPERVISED BY

*Prof. Dr. / Nahed Effat Youssef*

Professor of anesthesiology and intensive care

Faculty of Medicine-Ain Shams University

*Dr. / Alfred Maurice Said*

Assistant professor of anesthesiology and intensive care

Faculty of Medicine-Ain Shams University

*Dr. / Tarek Mohamed Ashoor*

Lecturer of anesthesiology and intensive care

Faculty of Medicine- Ain Shams University

Faculty of Medicine

Ain Shams University

200

## ACKNOWLEDGMENT

*First of all, I thank **GOD***

*I would like to express my deepest gratitude and sincere thanks to my principal supervisor **Prof. Dr. / Nahed Effat Youssef, Professor of anesthesiology and intensive care, Faculty of Medicine, Ain Shams University**, for her continuous encouragement and constructive guidance in the initiation and progress of this work.*

*I would like to express my deepest thanks and appreciation to **Dr./Alfred Maurice Said, assistant professor of anesthesiology and intensive care, Faculty of Medicine, Ain Shams University**, for his great support, helpful suggestion and sincere effort.*

*I also fell obliged to **Dr. / Tarek Mohamed Ashoor, Lecturer of anesthesiology and intensive care, Faculty of Medicine, Ain Shams University**, who helped me in this work to the very last detail.*

*Finally, to **my family** for their great psychological and moral support.*

*Sherin Dawoud Youssef.*

*Cairo, 2009*

Contents	Page
List of tables.....	1
List of abbreviations.....	2
Introduction.....	5
Patho- physiology of transplanted heart.....	6
Pharmacology of immunosuppressive drugs.....	32
Anesthetic management.....	46
Special cases.....	65
English summary.....	77
References.....	79
Arabic summary.....	91

## **List of tables**

Contents	Table
Indirect acting cardioactive drugs.....	1
Mixed direct and indirect acting sympathomimetic drugs.....	2
International society for heart and lung transplantation standardized endomyocardial biopsies grading scheme.....	3
Drugs that affect cyclosporine and tacrolimus blood levels.....	4
Drugs that may cause renal dysfunction when administrated with cyclosporine or tacrolimus.....	5
Preoperative investigations.....	6
Selected intraoperative management goals.....	7
Immunosuppressive therapies for pregnant transplanted recipient.....	8

## **List of abbreviations**

<b>ACE</b>	Angiotensin-converting enzyme
<b>ANP</b>	Atrial natriuretic peptide
<b>ARB</b>	Angiotensin receptor blockers
<b>ARDS</b>	Adult respiratory distress syndrome
<b>ATG</b>	Antithymocyte globulin
<b>ATGAM</b>	Antithymocyte gamma-globulin
<b>AV</b>	Atrioventricular
<b>BNP</b>	B-type natriuretic peptide
<b>BP</b>	Blood pressure
<b>CAD</b>	Coronary artery disease
<b>CARGO</b>	Cardiac allograft gene expression observation
<b>CAV</b>	Cardiac allograft vasculopathy
<b>CHF</b>	Congestive heart failure
<b>CMV</b>	Cytomegalovirus
<b>CNS</b>	Central nervous system
<b>CSA</b>	Cyclosporine
<b>CVP</b>	Central venous pressure
<b>DM</b>	Diabetes mellitus
<b>EBV</b>	Ebstein-Barr virus
<b>ECG</b>	Electrocardiogram

<b>EDV</b>	End-diastolic volume
<b>EF</b>	Ejection fraction
<b>EMB</b>	Endomyocardial biopsies
<b>Epi</b>	Epinephrine
<b>FDA</b>	Food and drug administration
<b>GIT</b>	Gastrointestinal
<b>GMP</b>	Guanosine monophosphate
<b>HDL</b>	High-density lipoprotein cholesterol
<b>HIV</b>	Human immunodeficiency virus
<b>HLA</b>	Human leukocyte antigen
<b>HR</b>	Heart rate
<b>HSV</b>	Herpes simplex viruses
<b>IL-2R</b>	Interleukin-2 receptor
<b>IMP</b>	Inosine monophosphate
<b>ISHLT</b>	International society for heart and lung transplantation
<b>IUGR</b>	Intrauterine growth retardation
<b>IV</b>	Intravenous
<b>IVUS</b>	Intravascular ultrasound
<b>LDL</b>	Low-density lipoprotein cholesterol
<b>MAC</b>	Minimum alveolar concentration
<b>MMF</b>	Mycophenolate mofetil

<b>MPS</b>	Mycophenolate sodium
<b>MRI</b>	Magnetic resonance imaging
<b>NDMR</b>	Nondepolarizing muscle relaxant
<b>NE</b>	Norepinephrine
<b>NSVT</b>	Nonsustained ventricular tachycardia
<b>OHT</b>	Orthotopic Heart Transplant
<b>PAP</b>	Pulmonary artery pressure
<b>PCP</b>	Pneumocystis carinii pneumonia
<b>PTLD</b>	Post-transplant lymphoproliferative disease
<b>PVCs</b>	Premature ventricular beats
<b>RBBB</b>	Right bundle branch block
<b>SA</b>	Sinoatrial
<b>SV</b>	Stroke volume
<b>TAC</b>	Tacrolimus
<b>TEE</b>	Transesophageal echocardiography
<b>TNF</b>	Tumor necrosis factor
<b>TOR</b>	Target of rapamycin inhibitors.
<b>VLDL</b>	Very low-density lipoprotein
<b>VVO</b> <b>Pace maker</b>	It paces the ventricle, senses the ventricle with fixed rate

# **INTRODUCTION**

Heart transplantation as a treatment for end-stage heart disease proved to be an accepted therapeutic modality only after the introduction of cyclosporine immunosuppression in the early 1980s (*Pochettino A. et al., 2000*).

Survival statistics reported by the International Society of Heart and Lung Transplantation (ISHLT) showed improved long-term survival that implies a further rise in the population of living cardiac allograft recipients and so, increased chance that anesthesiologists encounter those patients in their daily practice (*Manuel L. and Stanley H., 1997*).

The cardiac transplant recipient may return to the operating room for a minor surgical procedure, such as incision and drainage of a skin abscess, or for major surgeries, such as laparotomy for perforation of the bowels, stomach, and esophagus, and laparotomy for pancreatic disease, cholecystitis, appendicitis, and incarcerated inguinal hernias (*Kostopanagiotou G. et al., 1999*).

The cause of these complications is multifactorial. The debilitated preoperative condition of the recipient consequent to circulatory failure and nutritional deficits, accentuated by the stress of surgery, may make those patients more susceptible to complications after transplantation. In addition, immunosuppressive therapy may directly or indirectly contribute to both early and late complications (*Manuel L. and Stanley H., 1997*).



# **PATHOPHYSIOLOGY OF THE** **TRANSPLANTED HEART**

Heart transplantation is a widely accepted therapy for most patients under 65 years of age with advanced heart failure who remain symptomatic with the expectation of high or intermediate term mortality, despite optimal heart failure medications. Heart transplantation should be reserved for those patients most likely to benefit in terms of both life expectancy and quality of life. With over 30 years of experience, heart transplantation has been the most scrutinized and intensively studied therapy for advanced heart failure (*Kirklin JK. et al., 2004*).

Today, the better understanding of immune mechanisms in allograft rejection and the subsequent development of new immunosuppressive treatment regimens, improved postoperative follow-up care management. Moreover new donor organ preservation and transport systems, dramatically improves survival rates for heart transplant recipients. Recent data from the ISHLT registry have shown that the overall graft half-time (time at which 50% of those transplanted remain alive) has been increasing steadily, nowadays reaching over 10 years (*Taylor DO. et al., 2008*).

## **Physiology Of Cardiac Nerves**

A thorough knowledge of the principles of cardiovascular physiology is the foundation for the practice of cardiovascular anesthesia. It serves as the basis of understanding the patient's pharmacologic and surgical management.

## **Sympathetic System**

Nerves of the heart originate from sympathetic neurons of thoracolumbar region. Sympathetic fibers come from the stellate ganglion and the caudal halves of the cervical sympathetic trunks below the level of the cricoid cartilage. Transmission through the sympathetic ganglia occurs by release of acetylcholine, which interacts with the postsynaptic nicotinic cholinergic receptors on the postganglionic neurons. This stimulates norepinephrine release at the neuroeffector junction to activate B<sub>1</sub> adrenergic receptors (*Janes RD. et al., 1986*).

## **Parasympathetic System**

Parasympathetic preganglionic neurons arise in the medulla oblongata in the dorsal vagal nucleus and the nucleus ambiguus. These fibers enter the thorax as branches from the recurrent laryngeal and thoracic vagus nerve. Ganglia within the heart usually close to the structures innervated by the short postganglionic neurons. Postganglionic transmission occurs from stimulation of nicotinic cholinergic receptors at the postganglionic junction by acetylcholine. Release of acetylcholine at the neuroeffector junction activates muscarinic receptors in the heart (*Carol L., 1996*).

## **Neural Regulation**

Although the dominance of either the sympathetic or the parasympathetic system varies with age, situation, and physical condition, the inhibitory parasympathetic system is usually predominant. Parasympathetic stimulation, particularly of the right vagus nerve, decrease heart rate by

slowing the sinoatrial (SA) node. Vagal stimulation tends to suppress ventricular automaticity, which may facilitate termination of ventricular dysrhythmias. Intense vagal stimulation depresses both atrial and ventricular contractility by stimulation of cardiac muscarinic receptors (*Marneffe M. et al., 1986*).

Stimulation of the stellate ganglion or other sympathetic cardiac fibers increases heart rate (HR), contractility, and ejection fraction (EF). The right stellate ganglion has a greater effect on HR, whereas the left has more effect on contractility. Abnormalities of sympathetic cardiac nerve tone occur in long QT interval syndromes (*Carol L., 1996*).

### **Physiology Of The Denervated Heart**

Cardiac denervation is an inevitable consequence, as the cardiac plexus is divided in the donor, resulting in a denervated donor heart (*Ramakrishna H. et al., 2009*).

The atrial remnant of the recipient remains innervated, but no impulses will cross the suture line. As a result, the donor atrium is responsible for heart rate generation. The transplanted heart has a higher intrinsic rate and reduced rate variability. Resting heart rates range from 90 to 110. The loss of vagal input causes an increase in automaticity of the sinoatrial (SA) and atrioventricular (AV) nodes (*Keegan MT. and Plevak DJ., 2004*).

Normal responses to changes in position, e.g. orthostatic changes, are lost as are the variation in response to stimuli such as the Valsalva manoeuvre,

carotid sinus massage as well as normal responses to laryngoscopy and intubation (*Kostopanagiotou G. et al., 1999*).

Intrinsic function such as cardiac impulse formation and conduction are intact. The Frank-Starling mechanism is also intact. In the innervated heart, the normal acute response to sudden reduction in intravascular volume is simultaneous increase in both heart rate and contractility (*Ramakrishna H. et al., 2009*).

In the denervated heart there is an increase in cardiac output in the exercise state, however the mechanisms involved in the increase are different in the early stages than in the late stages of exercise. As opposed to normal hearts which initially increase output predominantly using rate, at the beginning of exercise, transplant patients increase output using Frank-Starling mechanisms by increasing the stroke volume (SV) and end-diastolic volume (EDV) (*Keegn MT. and plevak DJ., 2004*).

This is mediated through the autonomic nervous system which still controls the splanchnic bed. At maximal exercise the EDV is equal to that of resting state; however there is an increase in the heart rate, ejection fraction and stroke volume all due to the increase of circulating catecholamines (*Manuel L. and Stanley H., 1997*).

The transplanted heart is, therefore, critically preload dependent; higher filling pressures are needed, and this has to be kept in mind before the induction of general and regional anesthesia (*Manuel L. and Stanley H., 1997*).

A further study showed that, reinnervation is an ongoing process with different effects on various regions of the heart and not completed until 15

years after transplantation. Reinnervation affects the sensation of chest pain, regional regulation of myocardial blood flow and substrate metabolism also ventricular function and exercise performance will improve (*Bengel FM. et al., 2000*).

### **Denervation And Pharmacodynamic**

The actions of the sympathetic and parasympathetic nerve signals on the cardiovascular system are regulated by several means, including presynaptic receptors (adrenergic or cholinergic), which promote or inhibit neurotransmitter release. After denervation, these regulatory processes are no longer functional and "normal" response to cardioactive and vasoactive agents may be altered because of presynaptic consequences of nerve loss or postsynaptic changes related to the respective receptor-effector system (*Bristow MR., 1990*).

Drugs whose cardiovascular actions are dependent on the autonomic nervous system (atropine, edrophonium, hydralazine, pancuronium) have no effects in the denervated heart (Table 1) (*Manuel L. and Stanley H., 1997*).

*Isoproterenol and dobutamine* have similar effects in both denervated and normal hearts. Therefore, they are both effective inotropes in the denervated heart. They increase myocardial contractility more than dopamine (*Manuel L. and Stanley H., 1997*).

Drugs	Heart Rate		Blood Pressure	
	Innervated	Denervated	Innervated	Denervated
Atropine	↑	NR	↑±	NR
Edrophonium	↓	NR	NR	NR
Neostigmine	↓	NR	NR	NR
Pancuronium	↑	↓	NR	NR
Hydralazine	↑	NR	↓↓	↓↓
Amyl nitrite	↑	NR	↓	↓↓
Digoxin	↓	NR	NR	NR
↑=increase; ↓= decrease; NR= no response; ↑±=either small increase or no change.				

**Table (1)**Indirect Acting Cardioactive Drugs (*Manuel L. and Stanley H., 1997*).

Similarly *sympathomimetic* drugs that act indirectly by releasing neuronal norepinephrine(NE) have a blunted effect on transplanted hearts (Table 2) (*Csete M. and Sopher MJ. , 1994*).

Drugs	Mechanism of Action	Cardiovascular Response	
		Innervated	Denervated
Ephedrine	Direct action: stimulation of beta-1, beta-2 and alpha.  Indirect action: through release of neuronal norepinephrine(NE).	↑HR and BP	Blunted response
Metaraminol	Alpha-1(predominant) and beta-1; causes release of NE; with chronic use , act as a false neurotransmitter	↓ HR (reflex) and ↑ BP	BP response may be blunted; HR may ↑ (loss of baroreflex)
Dopamine	Alpha-1, alpha-2, beta-1, beta-2 and dopaminergic ; can also cause release of NE	↑ HR and ↑ BP (dose dependent)	Acts predominantly as a dopaminergic and vasoconstrictor
Mephentermine	Alpha-1, beta-1? beta-2; causes release of NE	↑ HR and ↑ BP(greater chronotropic effect)	Blunted response
HR=heart rate; BP=blood pressure; ↑=increase; ↓=decrease; ? =question.			

**Table (2)** Mixed direct and indirect acting sympathomimetic drugs (*Csete M. and Sopher MJ., 1994*).

*Nonadrenergic inotropes*, including the phosphodiesterase inhibitors (i.e., milrinone, amrinone, aminophylline, and glucagon), continue to be effective in the denervated heart. Because deafferentation and de-efferentation